Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed
First Professional Practice Guidelines Published for Psychedelic-Assisted Therapy
The American Psychedelic Practitioners Association (APPA) and BrainFutures announced the first-ever set of professional practice guidelines for psychedelic-assisted therapy. These guidelines aim to set a benchmark for practitioners in this emerging clinical field as informed by existing clinical research and expert consensus.
atai Life Sciences Announces Results of New Phase 1 Study of PCN-101 (R-Ketamine)
Atai announced results from Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine). The Phase 1 study assessed the safety, tolerability, and pharmacokinetic profile of PCN-101 delivered subcutaneously compared to PCN-101 delivered intravenously.
“…we believe these data support the concept of at-home use of PCN-101 in future studies.”
New Study Compares Psychedelics to Hypnosis and Meditation
A new study explores what happens in the brain while under the influence of psychedelics, meditation, and hypnosis. According to researchers, these states can be used together in therapeutic settings, but are not necessarily replacements for each other.
“Overall, these results extend our understanding of the mechanisms of action of ASC and highlight the importance of exploring how these effects can be leveraged in the treatment of psychiatric disorders.”
Optimi Health Announces CAD $3,000,000 Senior Debt Financing
Optimi announces the non-dilutive Debt Financing Agreement for proceeds of up to CAD $3,000,000. The company has already brought in the first tranche of CAD $1,000,000 from Catcher Investments Ltd., a company under the stewardship of Mr. JJ Wilson, who also serves as a director and non-executive Chair of Optimi Health.
